6,017 Shares in Kenvue Inc. (NYSE:KVUE) Acquired by C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 6,017 shares of the company’s stock, valued at approximately $128,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Grove Bank & Trust lifted its stake in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Riverview Trust Co acquired a new stake in Kenvue in the third quarter valued at approximately $30,000. Geneos Wealth Management Inc. acquired a new stake in Kenvue in the fourth quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new stake in Kenvue in the third quarter valued at approximately $35,000. Finally, Fortitude Family Office LLC lifted its stake in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Barclays reduced their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. UBS Group reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Citigroup reduced their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $23.00.

Kenvue Trading Up 2.3 %

Shares of KVUE stock opened at $21.94 on Friday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The firm’s fifty day simple moving average is $21.33 and its 200 day simple moving average is $22.02. The firm has a market capitalization of $42.07 billion, a P/E ratio of 41.40, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, sell-side analysts predict that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.74%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.